Where conditional marketing authorisations are granted, they should be restricted to situations where only the clinical part of the application dossier is less complete than normal. Incomplete pre-clinical or pharmaceutical data should be accepted only in the case of a product to be used in emergency situations, in response to public health threats.
Recital 4, Commission Regulation (EC) No 507/2006 of 29 March 2006 on the conditional marketing aut…
In forcesince 29 Mar 2006